[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mogad\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mogad":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100370705","clinical-and-imaging-cohort-of-neuroinflammation-diseases-in-china-clue-100370705",false,"NCT04106830","Clinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE)","Prospective Cohort Study of cLinical and Imaging Patterns of neUroinflammation disEases (CLUE)","Inclusion Criteria:\n\n* 16-75\n* Diagnosis of neuroinflammatory and demyelination disease\n* Availability of demographic and clinical data at the time disease onset\n* Informed written consent obtained from the patient, and\u002For patient's parent(s), and\u002For legal representative. Assent, if old enough to grant, will be obtained from all patients under the age of 16 years.\n\nExclusion Criteria:\n\n* Patients for whom MRI is contra-indicated\n* Patients included in an ongoing clinical trial where the product is blinded",true,"ALL","16 Years","75 Years",{"count":21,"type":22},1000,"ESTIMATED","12 Months","OBSERVATIONAL","CLUE is a prospective study to assess structural and functional changes of the brain, spinal cord, and optic nerve, as well as the inflammatory environment in patients with neuroinflammatory and demyelinating diseases. Participants will receive magnetic resonance (MR) techniques including DIR, DKI, QSM, Rs-fMRI, conventional sequences (T1WI\u002FT2WI\u002FFLAIR), and the MR metabolic SPICE sequence, and will be followed up for one year using 3T MRI. In addition, participants will receive a one-time baseline examination including T1WI, T2WI, FLAIR, and SWI sequences on 7T MRI, as well as PET-MRI.",[27,28,29,30],"NMO Spectrum Disorder","MRI","Multiple Sclerosis","MOGAD","RECRUITING","2026-06-12",{"date":34,"type":35},"2026-06-15","ACTUAL",{"date":37,"type":35},"2019-01-01",{"date":39,"type":22},"2028-12-31",{"name":41,"class":42},"Beijing Tiantan Hospital","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":4},"100629787","headache-prevalence-and-phenotype-in-myelin-oligodendrocyte-glycoprotein-antibody--associated-disease-mogad-100629787","NCT07479212","Headache Prevalence and Phenotype in Myelin Oligodendrocyte Glycoprotein Antibody -Associated Disease (MOGAD)","Single-center Ambispective Observational Study to Evaluate the Prevalence and Phenotype of Headache in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGHEAD).","MOGHEAD","Inclusion Criteria:\n\n* Patients older than 18 years with a diagnosis of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) according to the International MOGAD Panel proposed criteria\n* Ability to understand and provide written informed consent for the prospective cohort.\n\nExclusion Criteria:\n\n* Individuals under 18 years of age\n* Inability to provide informed consent for the prospective cohort","18 Years",{"count":54,"type":22},25,"Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) is an inflammatory demyelinating disorder of the central nervous system characterized by antibodies targeting myelin oligodendrocyte glycoprotein (MOG). Although the disease most commonly presents with optic neuritis, myelitis, or acute disseminated encephalomyelitis, headache has increasingly been reported as a potentially relevant and disabling symptom. However, the prevalence and clinical characteristics of headache in MOGAD remain poorly defined.\n\nThe purpose of this monocentric ambispective observational study is to evaluate the prevalence and clinical phenotype of headache in adult patients with MOGAD. The study aims to answer the following research questions: How common is headache in patients with MOGAD, what are its clinical characteristics, and does it show any correlation with any specific disease features?\n\nThe primary objective is to estimate the prevalence of acute and\u002For chronic headache in patients with MOGAD. Secondary objectives include describing headache characteristics (location, duration, intensity, associated symptoms, and response to treatment), assessing the presence and evolution of pre-existing primary headache disorders, and exploring potential associations between headache and laboratory or neuroradiological findings, including anti-MOG antibody titers, cerebrospinal fluid (CSF) oligoclonal bands, and the location of inflammatory or demyelinating lesions on MRI.\n\nApproximately 25 adult patients with MOGAD followed at the Multiple Sclerosis Center and Headache Clinic of the Fondazione Policlinico A. Gemelli IRCCS will be included. Clinical, laboratory, and neuroradiological data will be collected retrospectively and prospectively from medical records.",[30,57,58],"Migraine","Cephalalgia",[30,60,61],"Pain","Headache","NOT_YET_RECRUITING","2026-03-18",{"date":65,"type":35},"2026-03-20",{"date":67,"type":22},"2026-03-31",{"date":69,"type":22},"2026-12",{"name":71,"class":42},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":43},"100582589","frequency-of-fcgr3a-gene-polymorphisms-in-patients-with-neuromyelitis-optica-spectrum-disorders-anti-oligodendrocyte-myelin-protein-antibody-disease-and-multiple-sclerosis-100582589","NCT06865274","Frequency of FCGR3A Gene Polymorphisms in Patients With Neuromyelitis Optica Spectrum Disorders, Anti-oligodendrocyte Myelin Protein Antibody Disease, and Multiple Sclerosis.","Multicenter Prospective Interventional Study to Evaluate the Frequency of FCGR3A Gene Polymorphisms in Patients With Neuromyelitis Optica Spectrum Disorders, Myelin Oligodendrocyte Glycoprotein Antibody Disease, and Multiple Sclerosis.","PoGe","Inclusion Criteria:\n\n* Adult patients diagnosed with MS, NMOSD, or MOGAD receiving care at participating centers\n* Patients aged ≥ 18 years\n* Ability to understand and sign informed consent\n\nExclusion Criteria:\n\n* Individuals under 18 years of age\n* Inability to provide informed consent",{"count":81,"type":22},50,"INTERVENTIONAL",[84],"NA","The goal of this study is to assess the frequency of genetic polymorphisms of the FCG3A in a cohort of Italian patients affected by neuromyelitis optica spectrum disorder (NMOSD) and mog antibody associated disease (MOGAD) and in a a comparison group of patients affected with Multiple Sclerosis (MS).\n\nThe study will involve adult patients diagnosed with MS, NMOSD, or MOGAD, followed at various clinical centers in the Lazio region.\n\nPatients from the participating clinical centers will be selected, and their medical records will be analyzed to collect clinical and neuroimaging data. The data will include demographic information such as age, sex and body mass index and clinical information such as age at disease onset, disease duration, antibody status (AQP4+\u002F- and MOG+\u002F-), disease-modifying therapies, as well as MRI data and the Expanded Disability Status Scale (EDSS) score.\n\nEach patient included in the study will undergo a single blood draw of approximately 5 ml of peripheral venous blood during routine blood tests, which will be used for DNA extraction and polimorphysm analysis. Demographic and clinical differences between patients with NMOSD and MOGAD, with and without the polymorphism, will be assessed and compared with the group of patients with MS.",[87,30,29],"Neuromyelitis Optica Spectrum Disorders",[89,30,90,91,92],"NMOSD","MS","polymorphysm","FCG3A","2025-03-05",{"date":95,"type":35},"2025-03-07",{"date":97,"type":35},"2025-02-20",{"date":99,"type":22},"2027-02-28",{"name":71,"class":42}]